The Administration Core is the central core of the Mayo Clinic SPORE in Ovarian Cancer. It will provide organizational support for the leadership of the SPORE, facilitate communication among the component activities of the SPORE, and provide an organizational portal for collaborations outside the SPORE. Specifically, the Administration Core will: 1) provide leadership, organizational support, and financial management for SPORE investigators;2) oversee formal procedures for systematic scientific review of SPORE research projects;3) oversee and coordinate the efforts of all cores to ensure that the research projects are supported effectively;4) monitor'accrual, including minority accrual, to all SPORE clinical trials and biospecimen collections;5) provide administrative support to the Developmental Research Program and Career Developmental Program;6) assure ongoing integration and participation of the Ovarian SPORE in the activities of the Mayo Clinic Cancer Center;7) facilitate activities of the Ovarian SPORE advocates; 8) serve as the administrative liaison between the Mayo Clinic SPORE and the NCI SPORE Program, other Mayo SPOREs, and external collaborators;and 9) communicate SPORE-related research developments among the Mayo Clinic SPORE investigators, to the scientific community at large, and to the public. Dr. Hartmann will direct the Administration Core, in close consultation with the SPORE Co-PI/Administration Core Co-Director, and Executive Committee, to maximize the effectiveness of the Ovarian SPORE effort and its clinical-translational impact.
The Administration Core provides the organizational infrastructure necessary to perform the work proposed in this SPORE application.
|Karami, Sara; Han, Younghun; Pande, Mala et al. (2016) Telomere structure and maintenance gene variants and risk of five cancer types. Int J Cancer 139:2655-2670|
|Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589|
|Radecki Breitkopf, Carmen; Ridgeway, Jennifer L; Asiedu, Gladys B et al. (2016) Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. Clin Trials 13:660-664|
|Ezewuiro, Obiageli; Grushko, Tatyana A; Kocherginsky, Masha et al. (2016) Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One 11:e0147145|
|Li, Zheng; Block, Matthew S; Vierkant, Robert A et al. (2016) The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumour Biol 37:13279-13286|
|Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:|
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|Karyampudi, Lavakumar; Lamichhane, Purushottam; Krempski, James et al. (2016) PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-ÎºB. Cancer Res 76:239-50|
|French, Juliet D; Johnatty, Sharon E; Lu, Yi et al. (2016) Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget 7:6353-68|
|Harris, Faye R; Kovtun, Irina V; Smadbeck, James et al. (2016) Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers. Sci Rep 6:29831|
Showing the most recent 10 out of 225 publications